PCI Pharma expands serialisation tech at Wales site

PCI Pharma expands serialisation tech at Wales site

Outsourcing services provider PCI Pharma Services (PCI) has expanded its serialization capability at its Hay-on-Wye site in Wales.

The suite installation increases the site’s serialisation capability to support PCI’s clients in advance of meeting the implementation dates of the European Falsified Medicines Directive (EU FMD).

The highly flexible technology delivers machine and human-readable coding, tamper evident solutions and Bollini labelling – which in turn is linked to a case loading and aggregation station, with a final aggregation station compacting cases to pallet.

This investment in PCI’s Hay facility is the first phase of a multi-stage installation of expanded Serialization capacity at the site, complimenting a significant global initiative from PCI in developing its overall Serialization offering.

In February 2017, PCI announced an investment that will triple its Serialization capacity across its global network in preparation for the pending DCSCA deadline in November this year.

PCI has been actively serialising commercial products for the US, European and international markets for the past five years, and this investment in the Hay-on-Wye capabilities continues to demonstrate PCI’s market-leading position.

The company-wide software strategy enables operators in all PCI’s global locations to operate the same graphical user interface, providing a seamless global service.

PCI has partnered with Antares Vision, Crest Solutions and Xyntek for this latest installation, utilising Antares’ serialisation platform and technology architecture.

This installation supports a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.